Diabetic Retinopathy Management

Prevention and Risk Factor Management

• The American Diabetes Association recommends optimizing glycemic control to reduce the risk or slow the progression of diabetic retinopathy, aiming for near-normoglycemia 1, 2
• The American Heart Association suggests maintaining blood pressure control with targets <130/80 mmHg to decrease retinopathy progression 3, 4
• ACE inhibitors and ARBs are both effective treatments for blood pressure control in patients with diabetic retinopathy, as recommended by the American Diabetes Association 3, 4
• Optimizing serum lipid control can reduce the risk or slow progression of diabetic retinopathy, according to the American Diabetes Association 1, 4
• Consider adding fenofibrate, which may slow retinopathy progression particularly in patients with very mild nonproliferative diabetic retinopathy, as suggested by the American Diabetes Association 3, 4

Screening and Referral

• The American Academy of Ophthalmology recommends that patients with type 1 diabetes have an initial dilated eye examination within 5 years after diabetes onset 1, 5
• Patients with type 2 diabetes should have an initial dilated eye examination at the time of diagnosis, according to the American Diabetes Association 1, 5
• If no retinopathy is present and glycemia is well-controlled, exams every 1-2 years may be considered, as recommended by the American Diabetes Association 1, 3
• If any level of retinopathy is present, dilated retinal examinations should be performed at least annually, according to the American Academy of Ophthalmology 1, 5
• Promptly refer patients with any level of macular edema, severe nonproliferative diabetic retinopathy, or any proliferative diabetic retinopathy to an ophthalmologist experienced in managing diabetic retinopathy, as recommended by the American Diabetes Association 1, 6

Treatment Options Based on Disease Stage

For Diabetic Macular Edema (DME)

• The American Academy of Ophthalmology recommends anti-VEGF therapy (intravitreal injections) as the first-line treatment for center-involved diabetic macular edema with vision loss 3, 5
• Ranibizumab is FDA-approved for the treatment of diabetic retinopathy and has been shown to improve vision in patients with diabetic macular edema, according to the American Diabetes Association 3
• Most patients require near-monthly administration of intravitreal anti-VEGF agents during the first 12 months, with fewer injections in subsequent years, as recommended by the American Diabetes Association 3, 7
• Laser photocoagulation remains the preferred treatment for non-center-involved diabetic macular edema, according to the American Academy of Ophthalmology 5, 8

For Nonproliferative Diabetic Retinopathy (NPDR)

• Mild to moderate NPDR: Continue optimizing systemic factors (glycemic control, blood pressure, lipids), as recommended by the American Diabetes Association 1, 6
• Severe NPDR: Consider panretinal laser photocoagulation, especially in patients with type 2 diabetes or poor follow-up, according to the American Diabetes Association 1, 3

For Proliferative Diabetic Retinopathy (PDR)

• Panretinal laser photocoagulation (PRP) remains the mainstay treatment for proliferative diabetic retinopathy, as recommended by the American Diabetes Association 1, 3
• PRP has been shown to reduce the risk of severe vision loss from PDR from 15.9% to 6.4%, with greatest benefit in those with more advanced disease, according to the American Diabetes Association 3, 9

Special Considerations

• Pregnancy is associated with rapid progression of diabetic retinopathy; women with pre-existing diabetes who become pregnant should be examined early and closely during pregnancy, as recommended by the American Diabetes Association 3, 7
• Retinopathy is not a contraindication to aspirin therapy for cardioprotection, as aspirin does not increase the risk of retinal hemorrhage, according to the American Heart Association 1, 6

Common Pitfalls to Avoid

• Delaying referral to an ophthalmologist when macular edema or severe/proliferative retinopathy is present, as warned by the American Academy of Ophthalmology 1, 5
• Rapid implementation of intensive glycemic management in patients with existing retinopathy, which can cause early worsening, as cautioned by the American Diabetes Association 3
• Discontinuing aspirin therapy due to concerns about retinal hemorrhage, as advised against by the American Heart Association 1, 6
• Inadequate follow-up of patients with existing retinopathy, as warned by the American Diabetes Association 1, 3
• Neglecting blood pressure and lipid control while focusing only on glycemic control, as cautioned by the American Diabetes Association 1, 4

Evidence‑Based Management of Diabetic Retinopathy

Systemic Risk‑Factor Optimization

• Fenofibrate therapy slows the progression of diabetic retinopathy, especially in patients who start with very mild non‑proliferative disease. 10
• Both ACE inhibitors and angiotensin‑II receptor blockers effectively lower blood pressure and reduce retinopathy progression. 10
• Targeting systolic/diastolic blood pressure to <130/80 mmHg decreases retinopathy progression, while more aggressive targets (<120 mmHg systolic) do not provide additional benefit. 10
• Aspirin use does not increase the risk of retinal hemorrhage and should not be discontinued for ophthalmic reasons. 10

Ocular Treatment – Proliferative Diabetic Retinopathy (PDR)

• Panretinal photocoagulation (PRP) reduced the incidence of severe vision loss from 15.9 % in untreated eyes to 6.4 % in treated eyes, with the greatest benefit in eyes with disc neovascularization or vitreous hemorrhage. 11
• Intravitreal anti‑VEGF injections are non‑inferior to PRP for PDR and may achieve superior visual outcomes, provided patients can adhere to the required follow‑up schedule. 10
• Ranibizumab has received regulatory approval for the treatment of diabetic retinopathy. 10

Ocular Treatment – Diabetic Macular Edema (DME)

• Three anti‑VEGF agents are routinely employed for center‑involved DME: bevacizumab, ranibizumab, and aflibercept. 10
• Patients typically need near‑monthly anti‑VEGF injections during the first year, after which injection frequency can be reduced while maintaining disease remission. 10
• Anti‑VEGF therapy provides superior anatomical and functional outcomes compared with laser monotherapy or combined laser‑anti‑VEGF regimens for center‑involved DME. 10
• Focal/grid laser photocoagulation is no longer first‑line for center‑involved DME because anti‑VEGF agents achieve better visual results. 10

Special Considerations – Pregnancy

• Pregnancy in individuals with type 1 diabetes can exacerbate diabetic retinopathy, particularly when glycemic control at conception is suboptimal. 11
• Applying laser photocoagulation during pregnancy can reduce the risk of vision loss associated with disease progression. 11

Guideline Summary for Management of Diabetic Retinopathy

Systemic Management (Foundation for All Stages)

• Maintain intensive glycemic control with target HbA1c < 7 % to reduce the onset and slow progression of diabetic retinopathy. – American Academy of Ophthalmology 12
• Control blood pressure to < 130/80 mmHg using ACE inhibitors or ARBs, which has been shown to decrease retinopathy progression. – American Diabetes Association 13
• Optimize lipid profile and add fenofibrate in patients with very mild non‑proliferative diabetic retinopathy, as this regimen slows disease progression. – American Diabetes Association 13

Stage‑Specific Ocular Treatment

Mild to Moderate Non‑Proliferative Diabetic Retinopathy (NPDR)

• No ocular intervention is required; management should focus exclusively on systemic risk‑factor control. – American Academy of Ophthalmology 12
• Monitoring intervals: examine patients with mild NPDR every 6–12 months and those with moderate NPDR every 3–6 months. – American Academy of Ophthalmology 12

Severe Non‑Proliferative Diabetic Retinopathy

• Consider early pan‑retinal photocoagulation (PRP) for high‑risk individuals (poor compliance, impending cataract surgery, pregnancy, or advanced disease in the fellow eye). – American Academy of Ophthalmology 12

Proliferative Diabetic Retinopathy (PDR)

• Pan‑retinal photocoagulation reduces the risk of severe vision loss from 15.9 % to 6.4 %, with the greatest benefit in eyes with disc neovascularization or vitreous hemorrhage. – American Diabetes Association 13
• Intravitreal anti‑VEGF agents (ranibizumab, aflibercept, bevacizumab) are safe and effective alternatives for at least two years of follow‑up. – American Academy of Ophthalmology 12
• Select PRP over anti‑VEGF when patient adherence to frequent injections is uncertain or when long‑term follow‑up is not feasible. – American Academy of Ophthalmology 12

Diabetic Macular Edema (DME) Management

Center‑Involved DME with Vision Loss (≤ 20/30)

• First‑line therapy is intravitreal anti‑VEGF, which is superior to laser monotherapy. – American Diabetes Association 13
• Aflibercept 2 mg provides the best 1‑year visual outcomes, especially when baseline vision is ≤ 20/50. – American Diabetes Association 13
• Ranibizumab (0.3–0.5 mg) achieves comparable results to aflibercept by two years. – American Academy of Ophthalmology 12
• Bevacizumab (1.25 mg) yields similar outcomes in mild visual impairment but is less effective at reducing retinal thickening. – American Academy of Ophthalmology 12
• Treatment schedule: near‑monthly injections during the first 12 months, followed by reduced frequency in subsequent years. – American Diabetes Association 13

Center‑Involved DME with Good Vision (> 20/30)

• Close observation with anti‑VEGF initiated only if vision deteriorates provides comparable two‑year outcomes to immediate treatment. – American Diabetes Association 13

Non‑Center‑Involved DME

• Focal or grid laser photocoagulation remains the preferred therapy. – American Academy of Ophthalmology 14

Persistent DME despite Anti‑VEGF

• Consider macular laser photocoagulation or intravitreal corticosteroids as adjunctive options. – American Diabetes Association 13
• Intravitreal corticosteroids are reasonable first‑line agents for patients unable to receive anti‑VEGF (e.g., during pregnancy). – American Diabetes Association 13

Referral and Follow‑Up Schedule

• Urgent referral (within 1 month) for any proliferative diabetic retinopathy or center‑involved DME. – American Academy of Ophthalmology 12
• Non‑urgent referral (1–3 months) for severe or moderate NPDR. – American Academy of Ophthalmology 12
• No referral required for patients with no retinopathy or mild NPDR without macular edema; routine re‑examination every 1–2 years if glycemic control is good. – American Academy of Ophthalmology 12